<![CDATA[Type 2 diabetes mellitus is a chronic metabolic disease with a rising prevalence; some patients require insulin therapy to reach optimal glycemic control. Long-acting insulin, particularly insulin glargine and insulin detemir, serves as basal therapy. This study describes the prescribing profile of long-acting insulin among BPJS outpatients with type 2 diabetes mellitus at Hermina Kemayoran Hospital during October-December 2025. The study used a descriptive design with a retrospective approach. The population comprised 1,868 outpatients with type 2 diabetes mellitus. Samples were selected through purposive sampling based on inclusion criteria, and all eligible records were then included using total sampling. A total of 204 patients met the eligibility criteria. Data were collected from medical records and prescription data, covering sex, age, HbA1c results, and the type of long-acting insulin prescribed, then analyzed univariately and presented as frequencies and percentages. Female patients outnumbered male patients throughout the study period. Long-acting insulin use was concentrated among patients aged 46-65 years and older than 65 years. Insulin glargine was the most frequently prescribed type, accounting for 91.46% in October, 90.74% in November, and 94.12% in December, while insulin detemir was prescribed less often. The prescribing profile of long-acting insulin was dominated by female patients, older age groups, and insulin glargine use. These findings can serve as baseline data for evaluating insulin utilization and planning pharmaceutical care services.]]>
